Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL 10 versus ADHANSIA XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL 10 versus ADHANSIA XR.
ADDERALL 10 vs ADHANSIA XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adderall 10 contains a mixture of amphetamine salts (dextroamphetamine and levoamphetamine). Amphetamines are non-catecholamine sympathomimetic amines that promote the release of dopamine and norepinephrine from presynaptic neurons, inhibit their reuptake, and inhibit monoamine oxidase activity, thereby increasing extracellular levels of these neurotransmitters in the central nervous system.
Adhansia XR is a central nervous system (CNS) stimulant. The mechanism of action in attention deficit hyperactivity disorder (ADHD) is not fully known, but it is thought to involve blockade of norepinephrine and dopamine reuptake into presynaptic neurons, increasing their levels in the synaptic cleft. This enhances attention and reduces impulsivity.
10 mg orally once daily in the morning, with or without food; may increase by 5-10 mg weekly based on tolerability and response; usual effective dose 10-40 mg/day divided into 2-3 doses; maximum 60 mg/day.
Methylphenidate hydrochloride extended-release: Oral, 18-72 mg once daily in the morning.
None Documented
None Documented
Terminal elimination half-life: dextroamphetamine 9-11 hours, levoamphetamine 11-14 hours (Adderall is a mixed salt). In adults, mean half-life ~10 hours; in children, slightly shorter (6-8 hours). Clinical context: steady-state reached in 2-3 days; dosing interval typically 4-6 hours for immediate-release.
Mean terminal elimination half-life is 7.5 hours (range 5-10 hours) following oral administration, allowing twice-daily dosing.
Renal: 70-80% (30-40% as unchanged amphetamine; remainder as deaminated and hydroxylated metabolites). Fecal: minimal (<5%). Biliary: negligible. Urinary pH affects excretion: acidic urine increases elimination, alkaline urine decreases.
Primarily renal (78% as unchanged drug), with 10% biliary/fecal elimination.
Category C
Category C
CNS Stimulant
CNS Stimulant